Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy

Cancer Immunology Research

Volumn 5, Issue 12, 2017, Pages 1133-1140

  Lee, Hyunju ^a,b   Hodi, F Stephen ^c   Giobbie Hurder, Anita ^c   Ott, Patrick A ^c   Buchbinder, Elizabeth I ^c   Haq, Rizwan ^c   Tolaney, Sara ^c   Barroso Sousa, Romualdo ^c   Zhang, Kevin ^c   Donahue, Hilary ^c   Davis, Meredith ^c   Gargano, Maria E ^c   Kelley, Kristina M ^c   Carroll, Rona S ^a   Kaiser, Ursula B ^a   Min, Le ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b METROWEST MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; AGED; ANUS CANCER; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CLINICAL ARTICLE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GLIOBLASTOMA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LEIOMYOSARCOMA; MALE; MELANOMA; MIDDLE AGED; MONOTHERAPY; THYROID FUNCTION; THYROIDITIS; THYROTOXICOSIS; WEIGHT REDUCTION; COMPLICATION; DRUG EFFECT; IMMUNOLOGY; IMMUNOMODULATION; MOLECULARLY TARGETED THERAPY; NEOPLASM; THYROID DISEASE; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; CELL LINE, TUMOR; FEMALE; HUMANS; HYPOTHYROIDISM; IMMUNOMODULATION; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; THYROID DISEASES; THYROTOXICOSIS;

EID: 85037606593     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-17-0208     Document Type: Article

References (23)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–23.
3. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908–18.
4. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006–17.
5. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974–82.
6. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 2015;33: 3193–8.
7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
8. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122–33.
9. Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 2015;21:749–55.
10. Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 2016;19:82–92.
11. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014;21:371–81.
12. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134–44.
13. De Velasco G, Je Y, Bosse D, Awad MM, Ott PA, Moreira RB, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 2017;5:312–8.
14. Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014;99:4078–85.
15. Robert C, Joshua AM, Kefford R, Joseph RW, Wolchok JD, Hodi FS, et al. Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001. J Clin Oncol 2015;33 Suppl 9050.
16. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.
17. Orlov S, Salari F, Kashat L, Walfish PG. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab 2015;100: 1738–41.
18. Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 2015;1:433–40.
19. de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 2016;101: 4431–9.
20. Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2010;164: 303–7.
21. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521–32.
22. Ginsberg J, Walfish PG. Post-partum transient thyrotoxicosis with painless thyroiditis. Lancet 1977;1:1125–8.
23. Woolf PD. Transient painless thyroiditis with hyperthyroidism: a variant of lymphocytic thyroiditis? Endocr Rev 1980;1:411–20.